{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Tampa&page=47&state=Florida",
    "query": {
      "state": "Florida",
      "city": "Tampa",
      "page": 47
    },
    "page_size": 10
  },
  "pagination": {
    "page": 47,
    "page_size": 10,
    "total_count": 9133,
    "total_pages": 914,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Tampa&page=48&state=Florida&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Tampa&page=46&state=Florida&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-09T17:53:53.717Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00657501",
      "title": "Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypoactive Sexual Desire Disorder"
      ],
      "interventions": [
        {
          "name": "testosterone gel",
          "type": "DRUG"
        },
        {
          "name": "placebo gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioSante Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "30 Years to 65 Years · Female only"
      },
      "enrollment_count": 575,
      "start_date": "2008-03",
      "completion_date": "2011-09",
      "has_results": false,
      "last_update_posted_date": "2013-01-10",
      "last_synced_at": "2026-11-09T17:53:53.717Z",
      "location_count": 66,
      "location_summary": "Mobile, Alabama • Chandler, Arizona • Glendale, Arizona + 60 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00657501"
    },
    {
      "nct_id": "NCT03486873",
      "title": "Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Solid Tumors",
        "Hematologic Malignancies"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care (SOC)",
          "type": "DRUG"
        },
        {
          "name": "Lenvatinib",
          "type": "DRUG"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "MK-4280",
          "type": "DRUG"
        },
        {
          "name": "MK-4280A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab (+) Berahyaluronidase alfa",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3500,
      "start_date": "2018-08-21",
      "completion_date": "2043-08-04",
      "has_results": false,
      "last_update_posted_date": "2026-10-29",
      "last_synced_at": "2026-11-09T17:53:53.717Z",
      "location_count": 65,
      "location_summary": "Tucson, Arizona • Bakersfield, California • Fresno, California + 56 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03486873"
    },
    {
      "nct_id": "NCT00798629",
      "title": "Adenovirus CCL-21 Transduced MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma (Skin)"
      ],
      "interventions": [
        {
          "name": "Autologous dendritic cell-adenovirus CCL21 vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2008-11",
      "completion_date": "2012-04",
      "has_results": false,
      "last_update_posted_date": "2012-09-24",
      "last_synced_at": "2026-11-09T17:53:53.717Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00798629"
    },
    {
      "nct_id": "NCT05950945",
      "title": "Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Trastuzumab Deruxtecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 250,
      "start_date": "2023-12-30",
      "completion_date": "2027-10-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-12",
      "last_synced_at": "2026-11-09T17:53:53.717Z",
      "location_count": 5,
      "location_summary": "Miami Beach, Florida • Tampa, Florida • Boston, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Miami Beach",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Burlington",
          "state": "Massachusetts"
        },
        {
          "city": "Summit",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05950945"
    },
    {
      "nct_id": "NCT01351545",
      "title": "A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hematologic Malignancies",
        "Inherited Disorders of Metabolism",
        "Inherited Abnormalities of Platelets",
        "Histiocytic Disorders",
        "Acute Myelogenous Leukemia (AML or ANLL)",
        "Acute Lymphoblastic Leukemia (ALL)",
        "Other Acute Leukemia",
        "Chronic Myelogenous Leukemia (CML)",
        "Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases",
        "Other Leukemia",
        "Hodgkin Lymphoma",
        "Non-hodgkin Lymphoma",
        "Multiple Myeloma/ Plasma Cell Disorder (PCD)",
        "Inherited Abnormalities of Erythrocyte Differentiation or Function",
        "Disorders of the Immune System",
        "Autoimmune Diseases",
        "Severe Aplastic Anemia"
      ],
      "interventions": [
        {
          "name": "A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Center for International Blood and Marrow Transplant Research",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 99999,
      "start_date": "2011-10",
      "completion_date": "2041-10",
      "has_results": false,
      "last_update_posted_date": "2026-07-06",
      "last_synced_at": "2026-11-09T17:53:53.717Z",
      "location_count": 142,
      "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 90 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01351545"
    },
    {
      "nct_id": "NCT02258854",
      "title": "An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Uveitis"
      ],
      "interventions": [
        {
          "name": "Dose 2 gevokizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "XOMA (US) LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 69,
      "start_date": "2014-03",
      "completion_date": "2017-12",
      "has_results": false,
      "last_update_posted_date": "2015-10-16",
      "last_synced_at": "2026-11-09T17:53:53.717Z",
      "location_count": 33,
      "location_summary": "Chandler, Arizona • Phoenix, Arizona • Beverly Hills, California + 30 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Redlands",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02258854"
    },
    {
      "nct_id": "NCT02274766",
      "title": "Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dyskinesia",
        "Levodopa-Induced Dyskinesia (LID)",
        "Parkinson's Disease (PD)"
      ],
      "interventions": [
        {
          "name": "ADS-5102",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Adamas Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "30 Years to 85 Years"
      },
      "enrollment_count": 77,
      "start_date": "2014-10",
      "completion_date": "2016-03-10",
      "has_results": true,
      "last_update_posted_date": "2018-01-10",
      "last_synced_at": "2026-11-09T17:53:53.717Z",
      "location_count": 21,
      "location_summary": "Fountain Valley, California • Sunnyvale, California • Boca Raton, Florida + 18 more",
      "locations": [
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Sunnyvale",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Port Charlotte",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02274766"
    },
    {
      "nct_id": "NCT00098722",
      "title": "Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Maraviroc (UK-427,857)",
          "type": "DRUG"
        },
        {
          "name": "optimized background therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 474,
      "start_date": "2004-12",
      "completion_date": "2011-04",
      "has_results": true,
      "last_update_posted_date": "2012-05-16",
      "last_synced_at": "2026-11-09T17:53:53.717Z",
      "location_count": 62,
      "location_summary": "Hobson City, Alabama • Garden Grove, California • Los Angeles, California + 44 more",
      "locations": [
        {
          "city": "Hobson City",
          "state": "Alabama"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00098722"
    },
    {
      "nct_id": "NCT01144351",
      "title": "A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "ELND002",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Elan Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 32,
      "start_date": "2010-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2015-12-14",
      "last_synced_at": "2026-11-09T17:53:53.717Z",
      "location_count": 17,
      "location_summary": "Berkeley, California • Fresno, California • Newport Beach, California + 14 more",
      "locations": [
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01144351"
    },
    {
      "nct_id": "NCT07074977",
      "title": "Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Pruritus of Unknown Origin"
      ],
      "interventions": [
        {
          "name": "nemolizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Galderma R&D",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2025-10-20",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-27",
      "last_synced_at": "2026-11-09T17:53:53.717Z",
      "location_count": 25,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Fountain Valley, California + 22 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07074977"
    }
  ]
}